NYSE · SYK
Stryker Corporation
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
Loading market information…
NYSE · GMED · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Globus Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Globus Medical, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $1.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Globus Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $0.68-8.6% vs estimate | $598.12M-4.44% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | $0.84+13.51% vs estimate | $657.29M+1.8% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | $0.83+28.28% vs estimate | $625.71M+3.48% vs estimate |
|---|
THE ANALYST VIEW
36 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $97.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$97.47+$1.08 (+1.12%)
Zimmer Biomet Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.01% below the high.
$30.41+$0.29 (+0.96%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 18.01% below the high.
$11.37-$0.08 (-0.7%)
Alphatec Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.18% below the high.
$14.87+$0.22 (+1.5%)
Bioventus Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.44% below the high.
$22.41+$0.58 (+2.66%)
SI-BONE, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.35% below the high.
$31.52+$0.72 (+2.34%)
OrthoPediatrics Corp.’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
$10.24+$0.20 (+1.99%)
Orthofix Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
